Arthur A M Wilde

List of Publications by Year
in descending order

390	43,055	1163 111	2439 197
papers	citations	h-index	g-index

393	393	393	17468
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genotype-Phenotype Correlation in the Long-QT Syndrome. Circulation, 2001, 103, 89-95.	1.6	1,641
2	Brugada Syndrome: Report of the Second Consensus Conference. Circulation, 2005, 111, 659-670.	1.6	1,639
3	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 2013, 10, 1932-1963.	0.3	1,587
4	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm, 2011, 8, 1308-1339.	0.3	995
5	Proposed Diagnostic Criteria for the Brugada Syndrome. Circulation, 2002, 106, 2514-2519.	1.6	779
6	Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome. Circulation, 2010, 121, 635-643.	1.6	720
7	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	0.7	699
8	An Entirely Subcutaneous Implantable Cardioverterâ€“Defibrillator. New England Journal of Medicine, 2010, 363, 36-44.	13.9	686
9	An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm, 2010, 7, 33-46.	0.3	649
10	A Single Na ⁺ Channel Mutation Causing Both Long-QT and Brugada Syndromes. Circulation Research, 1999, 85, 1206-1213.	2.0	612
11	Mutation in the KCNQ1 Gene Leading to the Short QT-Interval Syndrome. Circulation, 2004, 109, 2394-2397.	1.6	603
12	Cardiac conduction defects associate with mutations in SCN5A. Nature Genetics, 1999, 23, 20-21.	9.4	549
13	Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nature Medicine, 2009, 15, 380-383.	15.2	539
14	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace, 2013, 15, 1389-1406.	0.7	494
15	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.3	494
16	Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nature Genetics, 2013, 45, 1044-1049.	9.4	467
17	Atlas of the clinical genetics of human dilated cardiomyopathy. European Heart Journal, 2015, 36, 1123-1135.	1.0	456
18	Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers. Journal of the American College of Cardiology, 2012, 59, 493-500.	1.2	449

#	Article	IF	Citations
19	â€œBrugadaâ€•Syndrome. Circulation, 1999, 99, 666-673.	1.6	442
20	Brugada Syndrome: Report of the Second Consensus Conference. Heart Rhythm, 2005, 2, 429-440.	0.3	429
21	Clinical Aspects of Type-1 Long-QT Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene. Circulation, 2007, 115, 2481-2489.	1.6	394
22	Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILIONÂ® long QT syndrome genetic test. Heart Rhythm, 2009, 6, 1297-1303.	0.3	389
23	Sudden Unexplained Death. Circulation, 2005, 112, 207-213.	1.6	384
24	Left Cardiac Sympathetic Denervation for Catecholaminergic Polymorphic Ventricular Tachycardia. New England Journal of Medicine, 2008, 358, 2024-2029.	13.9	377
25	Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circulation: Cardiovascular Genetics, 2015, 8, 437-446.	5.1	370
26	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. European Journal of Heart Failure, 2012, 14, 1199-1207.	2.9	369
27	Absence of Calsequestrin 2 Causes Severe Forms of Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation Research, 2002, 91, e21-6.	2.0	358
28	Flecainide Therapy Reduces Exercise-Induced Ventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Journal of the American College of Cardiology, 2011, 57, 2244-2254.	1.2	352
29	Drugs and Brugada syndrome patients: Review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm, 2009, 6, 1335-1341.	0.3	342
30	Risk stratification for sudden cardiac death: current status and challenges for the future. European Heart Journal, 2014, 35, 1642-1651.	1.0	341
31	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. European Heart Journal, 2015, 36, 847-855.	1.0	338
32	Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more?. Cardiovascular Research, 2005, 67, 367-378.	1.8	326
33	Plakophilin-2 Mutations Are the Major Determinant of Familial Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation, 2006, 113, 1650-1658.	1.6	326
34	The pathophysiological mechanism underlying Brugada syndrome. Journal of Molecular and Cellular Cardiology, 2010, 49, 543-553.	0.9	323
35	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Heart Rhythm, 2016, 13, e295-e324.	0.3	322
36	Genetic Testing for Long-QT Syndrome. Circulation, 2009, 120, 1752-1760.	1.6	319

#	Article	IF	Citations
37	Fibrosis, Connexin-43, and Conduction Abnormalities in the Brugada Syndrome. Journal of the American College of Cardiology, 2015, 66, 1976-1986.	1.2	315
38	The RYR2-Encoded Ryanodine Receptor/Calcium Release Channel in Patients Diagnosed Previously With Either Catecholaminergic Polymorphic Ventricular Tachycardia or Genotype Negative, Exercise-Induced Long QT Syndrome. Journal of the American College of Cardiology, 2009, 54, 2065-2074.	1.2	303
39	Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). Journal of the American College of Cardiology, 1999, 33, 327-332.	1.2	292
40	Proposed Diagnostic Criteria for the Brugada Syndrome. European Heart Journal, 2002, 23, 1648-1654.	1.0	281
41	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nature Genetics, 2014, 46, 826-836.	9.4	281
42	Two Distinct Congenital Arrhythmias Evoked by a Multidysfunctional Na ⁺ Channel. Circulation Research, 2000, 86, E91-7.	2.0	279
43	Subcutaneous or Transvenous Defibrillator Therapy. New England Journal of Medicine, 2020, 383, 526-536.	13.9	278
44	Clinical Aspects and Prognosis of Brugada Syndrome in Children. Circulation, 2007, 115, 2042-2048.	1.6	275
45	Reappraisal of Reported Genes for Sudden Arrhythmic Death. Circulation, 2018, 138, 1195-1205.	1.6	271
46	Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals. Journal of the American College of Cardiology, 2011, 57, 51-59.	1.2	268
47	SCN5A Mutations and the Role of Genetic Background in the Pathophysiology of Brugada Syndrome. Circulation: Cardiovascular Genetics, 2009, 2, 552-557.	5.1	262
48	Permanent Leadless Cardiac Pacing. Circulation, 2014, 129, 1466-1471.	1.6	257
49	Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. Journal of Medical Genetics, 2005, 42, 863-870.	1.5	250
50	Cardiomyocytes Derived From Pluripotent Stem Cells Recapitulate Electrophysiological Characteristics of an Overlap Syndrome of Cardiac Sodium Channel Disease. Circulation, 2012, 125, 3079-3091.	1.6	245
51	Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2015, 131, 2185-2193.	1.6	238
52	An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation, 2020, 141, 418-428.	1.6	238
53	Genotype-Phenotype Aspects of Type 2 Long QT Syndrome. Journal of the American College of Cardiology, 2009, 54, 2052-2062.	1.2	236
54	Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 606-616.	2.1	236

#	Article	IF	Citations
55	Not All Beta-Blockers Are Equal in the Management of Long QT Syndrome Types 1 and 2. Journal of the American College of Cardiology, 2012, 60, 2092-2099.	1.2	234
56	Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm, 2009, 6, 341-348.	0.3	224
57	Compound Heterozygosity for Mutations (W156X and R225W) inSCN5AAssociated With Severe Cardiac Conduction Disturbances and Degenerative Changes in the Conduction System. Circulation Research, 2003, 92, 159-168.	2.0	222
58	Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome. Journal of the American College of Cardiology, 2017, 69, 2134-2145.	1.2	219
59	Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. European Heart Journal, 2015, 36, 1290-1296.	1.0	217
60	Common Sodium Channel Promoter Haplotype in Asian Subjects Underlies Variability in Cardiac Conduction. Circulation, 2006, 113, 338-344.	1.6	215
61	Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm, 2016, 13, 443-454.	0.3	213
62	Expanding Spectrum of Human RYR2 -Related Disease. Circulation, 2007, 116, 1569-1576.	1.6	211
63	The Entirely Subcutaneous Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2012, 60, 1933-1939.	1.2	205
64	The Response of the QT Interval to the Brief Tachycardia Provoked by Standing. Journal of the American College of Cardiology, 2010, 55, 1955-1961.	1.2	198
65	Brugada Phenocopy: New Terminology and Proposed Classification. Annals of Noninvasive Electrocardiology, 2012, 17, 299-314.	0.5	198
66	Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events. Circulation, 2012, 125, 1988-1996.	1.6	187
67	Phenotypical Manifestations of Mutations in the Genes Encoding Subunits of the Cardiac Sodium Channel. Circulation Research, 2011, 108, 884-897.	2.0	185
68	Derivation and Validation of a Simple Exercise-Based Algorithm for Prediction of Genetic Testing in Relatives of LQTS Probands. Circulation, 2011, 124, 2187-2194.	1.6	182
69	Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovascular Research, 1999, 44, 507-517.	1.8	181
70	Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace, 2012, 14, 175-183.	0.7	174
71	Delay in Right Ventricular Activation Contributes to Brugada Syndrome. Circulation, 2004, 109, 1272-1277.	1.6	173
72	HCN4 Mutations in Multiple Families With Bradycardia and Left Ventricular Noncompaction Cardiomyopathy. Journal of the American College of Cardiology, 2014, 64, 745-756.	1.2	173

#	Article	IF	Citations
73	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Europace, 2017, 19, euw235.	0.7	172
74	Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nature Genetics, 2010, 42, 688-691.	9.4	170
75	Clinical Aspects of Type 3 Long-QT Syndrome. Circulation, 2016, 134, 872-882.	1.6	162
76	SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm, 2020, 17, 1456-1462.	0.3	162
77	Genetic testing for inherited cardiac disease. Nature Reviews Cardiology, 2013, 10, 571-583.	6.1	161
78	A Mutation in CALM1 Encoding Calmodulin in Familial Idiopathic Ventricular Fibrillation in Childhood and Adolescence. Journal of the American College of Cardiology, 2014, 63, 259-266.	1.2	160
79	A Gain-of-Function TBX5 Mutation Is Associated With Atypical Holtâ€“Oram Syndrome and Paroxysmal Atrial Fibrillation. Circulation Research, 2008, 102, 1433-1442.	2.0	158
80	Haplotype-Sharing Analysis Implicates Chromosome 7q36 Harboring DPP6 in Familial IdiopathicÂVentricular Fibrillation. American Journal of Human Genetics, 2009, 84, 468-476.	2.6	158
81	Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. European Heart Journal, 2007, 28, 2126-2133.	1.0	157
82	The Common Long-QT Syndrome Mutation KCNQ1/A341V Causes Unusually Severe Clinical Manifestations in Patients With Different Ethnic Backgrounds. Circulation, 2007, 116, 2366-2375.	1.6	157
83	Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: The experience of a tertiary referral center in The Netherlands. Heart Rhythm, 2010, 7, 1383-1389.	0.3	156
84	Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. American Heart Journal, 2012, 163, 753-760.e2.	1.2	156
85	Multifocal Ectopic Purkinje-Related Premature Contractions. Journal of the American College of Cardiology, 2012, 60, 144-156.	1.2	156
86	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	9.4	155
87	Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. Journal of the American College of Cardiology, 2016, 68, 2047-2055.	1.2	151
88	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm, 2021, 18, e1-e50.	0.3	151
89	A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes. Circulation: Cardiovascular Genetics, 2012, 5, 91-99.	5.1	150
90	Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience. European Journal of Heart Failure, 2013, 15, 628-636.	2.9	148

#	Article	IF	Citations
91	Outcome in Phospholamban R14del Carriers. Circulation: Cardiovascular Genetics, 2014, 7, 455-465.	5.1	146
92	Inherited cardiac arrhythmias. Nature Reviews Disease Primers, 2020, 6, 58.	18.1	146
93	Quinidine Induced Electrocardiographic Normalization in Two Patients with Brugada Syndrome. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1420-1422.	0.5	145
94	Familial Evaluation in Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 748-756.	2.1	144
95	Local Depolarization Abnormalities Are the Dominant Pathophysiologic Mechanism for Type 1 Electrocardiogram in Brugada Syndrome. Journal of the American College of Cardiology, 2010, 55, 789-797.	1.2	142
96	Possible Bradycardic Mode of Death and Successful Pacemaker Treatment in a Large Family with Features of Long QT Syndrome Type 3 and Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 2001, 12, 630-636.	0.8	140
97	Contribution of Sodium Channel Mutations to Bradycardia and Sinus Node Dysfunction in LQT3 Families. Circulation Research, 2003, 92, 976-983.	2.0	140
98	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.3	135
99	Yield of Molecular and Clinical Testing for Arrhythmia Syndromes. Circulation, 2013, 128, 1513-1521.	1.6	132
100	Fever Increases the Risk for Cardiac Arrest in the Brugada Syndrome. Annals of Internal Medicine, 2008, 149, 216.	2.0	131
101	The Brugada ECG Pattern. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 283-290.	2.1	129
102	The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. European Heart Journal, 2003, 24, 1848-1853.	1.0	127
103	Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. European Journal of Heart Failure, 2017, 19, 512-521.	2.9	127
104	Jâ€Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Journal of Arrhythmia, 2016, 32, 315-339.	0.5	125
105	Genetics of cardiac arrhythmias. Heart, 2005, 91, 1352-1358.	1.2	122
106	Slow and Discontinuous Conduction Conspire in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 379-386.	2.1	121
107	Genderâ€specific differences in major cardiac events and mortality in lamin A/C mutation carriers. European Journal of Heart Failure, 2013, 15, 376-384.	2.9	120
108	Genotype-Specific Onset of Arrhythmias in Congenital Long-QT Syndrome. Circulation, 2006, 114, 2096-2103.	1.6	117

#	Article	IF	Citations
109	Mutation and gender-specific risk in type 2 long QT syndrome: Implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm, 2011, 8, 1537-1543.	0.3	117
110	Which Patients Are Not Suitable for a Subcutaneous ICD: Incidence and Predictors of Failed QRSâ€Tâ€Wave Morphology Screening. Journal of Cardiovascular Electrophysiology, 2014, 25, 494-499.	0.8	117
111	Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. European Heart Journal, 2019, 40, 2964-2975.	1.0	116
112	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2â€"care pathways, treatment, and follow-up. European Heart Journal, 2022, 43, 1059-1103.	1.0	111
113	Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: A crossâ€sectional cohort study. American Journal of Medical Genetics, Part A, 2009, 149A, 602-612.	0.7	110
114	Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. Cardiovascular Research, 2015, 106, 520-529.	1.8	108
115	Channelopathies That Lead to Sudden Cardiac Death: Clinical and Genetic Aspects. Heart Lung and Circulation, 2019, 28, 22-30.	0.2	108
116	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022, 24, 1307-1367.	0.7	108
117	Activation Delay and VT Parameters in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Toward Improvement of Diagnostic ECG Criteria. Journal of Cardiovascular Electrophysiology, 2008, 19, 775-781.	0.8	102
118	The genetic architecture of long QT syndrome: A critical reappraisal. Trends in Cardiovascular Medicine, 2018, 28, 453-464.	2.3	100
119	Determination and Interpretation of the QT Interval. Circulation, 2018, 138, 2345-2358.	1.6	100
120	Exercise-Induced ECG Changes in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 531-539.	2.1	99
121	<scp>TECRL</scp>, a new lifeâ€threatening inherited arrhythmia gene associated with overlapping clinical features of both <scp>LQTS</scp> and <scp>CPVT</scp>. EMBO Molecular Medicine, 2016, 8, 1390-1408.	3.3	98
122	Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: do we need a scoring system?. European Heart Journal, 2006, 28, 575-580.	1.0	96
123	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. European Heart Journal, 2019, 40, 2953-2961.	1.0	96
124	A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. Heart Rhythm, 2019, 16, 403-410.	0.3	94
125	Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. Heart Rhythm, 2016, 13, 1274-1282.	0.3	89
126	Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2013, 10, 542-547.	0.3	88

#	Article	IF	Citations
127	Enhanced Classification of Brugada Syndromeâ€“Associated and Long-QT Syndromeâ€“Associated Genetic Variants in the SCN5A -Encoded Na _v 1.5 Cardiac Sodium Channel. Circulation: Cardiovascular Genetics, 2015, 8, 582-595.	5.1	87
128	Genetically Determined Differences in Sodium Current Characteristics Modulate Conduction Disease Severity in Mice With Cardiac Sodium Channelopathy. Circulation Research, 2009, 104, 1283-1292.	2.0	86
129	Active Cascade Screening in Primary Inherited Arrhythmia Syndromes. Journal of the American College of Cardiology, 2010, 55, 2570-2576.	1.2	86
130	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
131	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008509.	2.1	82
132	The ICD for Primary Prevention in Patients With Inherited Cardiac Diseases. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 91-100.	2.1	78
133	European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death. European Journal of Human Genetics, 2019, 27, 1763-1773.	1.4	78
134	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022, 19, e1-e60.	0.3	78
135	Unique Cardiac Purkinje Fiber Transient Outward Current Î²-Subunit Composition. Circulation Research, 2013, 112, 1310-1322.	2.0	77
136	Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. European Heart Journal, 2011, 32, 1161-1170.	1.0	76
137	Sudden Death in the Young. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 96-104.	2.1	75
138	A Novel Early Onset Lethal Form of Catecholaminergic Polymorphic Ventricular Tachycardia Maps to Chromosome 7p14-p22. Journal of Cardiovascular Electrophysiology, 2007, 18, 1060-1066.	0.8	74
139	Diagnosis, management and therapeutic strategies for congenital long QT syndrome. Heart, 2022, 108, 332-338.	1.2	73
140	Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. Journal of Clinical Investigation, 2008, 118, 2552-61.	3.9	73
141	The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome. Journal of Medical Genetics, 2003, 40, 141-145.	1.5	72
142	Idiopathic Ventricular Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	72
143	Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing. Circulation, 2018, 137, 619-630.	1.6	72
144	Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation Journal, 2016, 80, 1285-1291.	0.7	71

#	Article	IF	Citations
145	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2018, 15, 1394-1401.	0.3	71
146	Genetic susceptibility for COVID-19â€“associated sudden cardiac death in African Americans. Heart Rhythm, 2020, 17, 1487-1492.	0.3	71
147	Impact of Leadless Pacemaker Therapy on Cardiac and Atrioventricular Valve Function Through 12 Months of Follow-Up. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007124.	2.1	70
148	Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. Europace, 2013, 15, 1042-1049.	0.7	69
149	Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Netherlands Heart Journal, 2010, 18, 248-254.	0.3	68
150	The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. European Heart Journal, 2010, 31, 842-848.	1.0	68
151	Prognostic significance of fever-induced Brugada syndrome. Heart Rhythm, 2016, 13, 1515-1520.	0.3	68
152	Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance. Europace, 2016, 18, 1740-1747.	0.7	68
153	Cardiac ryanodine receptor calcium release deficiency syndrome. Science Translational Medicine, 2021, 13, .	5.8	68
154	SCN5A Mutations in Brugada Syndrome Are Associated with Increased Cardiac Dimensions and Reduced Contractility. PLoS ONE, 2012, 7, e42037.	1.1	66
155	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. Heart Rhythm, 2018, 15, 1457-1465.	0.3	65
156	hiPSC-derived cardiomyocytes from Brugada Syndrome patients without identified mutations do not exhibit clear cellular electrophysiological abnormalities. Scientific Reports, 2016, 6, 30967.	1.6	64
157	Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. Journal of Neurology, 1997, 244, 657-663.	1.8	63
158	The Brugada Syndrome Susceptibility Gene HEY2 Modulates Cardiac Transmural Ion Channel Patterning and Electrical Heterogeneity. Circulation Research, 2017, 121, 537-548.	2.0	63
159	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace, 2020, 22, 1147-1148.	0.7	62
160	Phylogenetic and Physicochemical Analyses Enhance the Classification of Rare Nonsynonymous Single Nucleotide Variants in Type 1 and 2 Long-QT Syndrome. Circulation: Cardiovascular Genetics, 2012, 5, 519-528.	5.1	61
161	Somatic mosaicism contributes to phenotypic variation in Timothy syndrome. American Journal of Medical Genetics, Part A, 2011, 155, 2578-2583.	0.7	60
162	Effect of age and gender on the QTc-interval in healthy individuals and patients with long-QT syndrome. Trends in Cardiovascular Medicine, 2018, 28, 64-75.	2.3	60

#	Article	IF	Citations
163	Founder mutations in the Netherlands. Netherlands Heart Journal, 2009, 17, 422-428.	0.3	59
164	A comprehensive evaluation of the genetic architecture of sudden cardiac arrest. European Heart Journal, 2018, 39, 3961-3969.	1.0	59
165	Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm, 2012, 9, 892-898.	0.3	58
166	GNB5 Mutations Cause an Autosomal-Recessive Multisystem Syndrome with Sinus Bradycardia and Cognitive Disability. American Journal of Human Genetics, 2016, 99, 704-710.	2.6	58
167	Catecholaminergic polymorphic ventricular tachycardia: from bench to bedside. Heart, 2013, 99, 497-504.	1.2	57
168	Expert cardiologists cannot distinguish between Brugada phenocopy and Brugada syndrome electrocardiogram patterns. Europace, 2016, 18, 1095-1100.	0.7	57
169	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Heart Rhythm, 2018, 15, 716-724.	0.3	57
170	Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. European Heart Journal, 2022, 43, 1500-1510.	1.0	57
171	Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: The patients' perspective. American Journal of Medical Genetics, Part A, 2009, 149A, 1444-1451.	0.7	56
172	Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?. European Heart Journal, 2021, 42, 1073-1081.	1.0	56
173	Novel KCNQ1 and HERG missense mutations in Dutch long-QT families. , 1999, 13, 301-310.		55
174	Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores. European Heart Journal, 2019, 40, 3097-3107.	1.0	55
175	Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriersâ€“reaching the frontiers of individual risk prediction. European Heart Journal, 2021, 42, 2842-2850.	1.0	54
176	Switch From Fetal to Adult SCN5A Isoform in Human Induced Pluripotent Stem Cellâ€“Derived Cardiomyocytes Unmasks the Cellular Phenotype of a Conduction Diseaseâ€“Causing Mutation. Journal of the American Heart Association, 2017, 6, .	1.6	54
177	Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of Î²-blockade. Heart Rhythm, 2016, 13, 609-613.	0.3	53
178	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. Journal of the American College of Cardiology, 2019, 73, 1756-1765.	1.2	53
179	Implantation of the Subcutaneous Implantable Cardioverter-Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2017, 10, e004663.	2.1	52
180	Novel Brugada syndromeâ€“causing mutation in ionâ€“conducting pore of cardiac Na⁺ channel does not affect ion selectivity properties. Acta Physiologica Scandinavica, 2005, 185, 291-301.	2.3	51

#	Article	IF	Citations
181	Lamin A/C -Related Cardiac Disease. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	51
182	Adenosine Induced Ventricular Arrhythmias in the Emergency Room. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 450-455.	0.5	50
183	Accelerated Sinus Rhythm Prevents Catecholaminergic Polymorphic Ventricular Tachycardia in Mice and in Patients. Circulation Research, 2013, 112, 689-697.	2.0	50
184	Inherited ion channel diseases: a brief review. Europace, 2015, 17, ii1-ii6.	0.7	50
185	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart, 2016, 102, 303-312.	1.2	50
186	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 1-28.	0.5	49
187	Detailed characterization of familial idiopathic ventricular fibrillation linked to the DPP6 locus. Heart Rhythm, 2016, 13, 905-912.	0.3	48
188	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 92-100.	0.5	48
189	Everybody has Brugada syndrome until proven otherwise?. Heart Rhythm, 2015, 12, 1595-1598.	0.3	47
190	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms ofCASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2020, 142, 932-947.	1.6	44
191	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
192	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	3.9	42
193	Long-Term Outcome of Patients Initially Diagnosed With Idiopathic Ventricular Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	41
194	Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/â^' and human SCN5A-1795insD+/â^' iPSC-derived cardiomyocytes. Cardiovascular Research, 2017, 113, 829-838.	1.8	41
195	Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing. American Heart Journal, 2019, 214, 167-174.	1.2	41
196	Assessment and Validation of a Phenotype-Enhanced Variant Classification Framework to Promote or Demote RYR2 Missense Variants of Uncertain Significance. Circulation Genomic and Precision Medicine, 2019, 12, e002510.	1.6	41
197	SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families. Circulation Genomic and Precision Medicine, 2020, 13, e002911.	1.6	41
198	Gender differences in the long QT syndrome: effects of Î²-adrenoceptor blockade. Cardiovascular Research, 2002, 53, 770-776.	1.8	40

#	Article	IF	Citations
199	Characterization of a novel SCN5A mutation associated with Brugada syndrome reveals involvement of DIIIS4â€“S5 linker in slow inactivation. Cardiovascular Research, 2007, 76, 418-429.	1.8	40
200	Mortality of Inherited Arrhythmia Syndromes. Circulation: Cardiovascular Genetics, 2012, 5, 183-189.	5.1	39
201	An International Multicenter Evaluation of Type 5 Long QT Syndrome. Circulation, 2020, 141, 429-439.	1.6	39
202	Long-Term (Subacute) Potassium Treatment in Congenital HERG-Related Long QT Syndrome (LQTS2). Journal of Cardiovascular Electrophysiology, 1999, 10, 229-233.	0.8	38
203	The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling. Journal of Molecular and Cellular Cardiology, 2010, 49, 95-105.	0.9	38
204	The yield of postmortem genetic testing in sudden death cases with structural findings at autopsy. European Journal of Human Genetics, 2020, 28, 17-22.	1.4	38
205	Epidemiology of inherited arrhythmias. Nature Reviews Cardiology, 2020, 17, 205-215.	6.1	37
206	Drug-Induced J Point Elevation.. Journal of Cardiovascular Electrophysiology, 1999, 10, 219-223.	0.8	35
207	A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2022, 43, e1-e9.	1.0	35
208	Yield and Pitfalls of Ajmaline Testing in theÂEvaluation of Unexplained Cardiac Arrest and Sudden Unexplained Death. JACC: Clinical Electrophysiology, 2017, 3, 1400-1408.	1.3	34
209	Efficacy of an implantable cardioverter-defibrillator in a neonate with LQT3 associated arrhythmias. Europace, 2005, 7, 77-84.	0.7	33
210	Recurrent and founder mutations in the Netherlands. Netherlands Heart Journal, 2010, 18, 583-591.	0.3	33
211	SCN5A mutations in 442 neonates and children: genotypeâ€“phenotype correlation and identification of higher-risk subgroups. European Heart Journal, 2018, 39, 2879-2887.	1.0	33
212	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2â€”care pathways, treatment, and follow-up. Cardiovascular Research, 2022, 118, 1618-1666.	1.8	32
213	Beta-Blockers in the Treatment of Congenital Long QT Syndrome. Journal of the American College of Cardiology, 2014, 64, 1359-1361.	1.2	31
214	Arrhythmogenic Right Ventricular Cardiomyopathy. JACC: Clinical Electrophysiology, 2022, 8, 533-553.	1.3	31
215	Low rate of cardiac events in first-degree relatives of diagnosis-negative young sudden unexplained death syndrome victims during follow-up. Heart Rhythm, 2014, 11, 1728-1732.	0.3	30
216	Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation. Circulation Genomic and Precision Medicine, 2018, 11, e001424.	1.6	30

#	Article	IF	Citations
217	IK1 modulates the U-wave: insights in a 100-year-old enigma. Heart Rhythm, 2009, 6, 393-400.	0.3	29
218	Improving usual care after sudden death in the young with focus on inherited cardiac diseases (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	29
219	The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status update. Netherlands Heart Journal, 2019, 27, 480-486.	0.3	29
220	The role of reninâ€“angiotensinâ€“aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. European Journal of Human Genetics, 2012, 20, 1071-1077.	1.4	28
221	Readthrough-Promoting Drugs Gentamicin and PTC124 Fail to Rescue Na _v 1.5 Function of Human-Induced Pluripotent Stem Cellâ€“Derived Cardiomyocytes Carrying Nonsense Mutations in the Sodium Channel Gene SCN5A. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	28
222	Improving electrocardiogram-based detection of rare genetic heart disease using transfer learning: An application to phospholamban p.Arg14del mutation carriers. Computers in Biology and Medicine, 2021, 131, 104262.	3.9	28
223	Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiology, 2022, 7, 84.	3.0	28
224	Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial. Circulation, 2022, 145, 321-329.	1.6	28
225	An International Multicenter Cohort Study on Î²-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2022, 145, 333-344.	1.6	28
226	Postmortem Histopathological Examination of a Leadless Pacemaker Shows Partial Encapsulation After 19 Months. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1293-1295.	2.1	27
227	Relationship Between Cardiac Dysfunction and Cerebral Perfusion in Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocritical Care, 2016, 24, 202-206.	1.2	27
228	Cardiac abnormalities in athletes after SARS-CoV-2 infection: a systematic review. BMJ Open Sport and Exercise Medicine, 2021, 7, e001164.	1.4	27
229	Effect of Age and Sex on the QTc Interval in Children and Adolescents With Type 1 and 2 Long-QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	26
230	Heart failure following STEMI: a contemporary cohort study of incidence and prognostic factors. Open Heart, 2017, 4, e000551.	0.9	26
231	Computer versus cardiologist: Is a machine learning algorithm able to outperform an expert in diagnosing a phospholamban p.Arg14del mutation on the electrocardiogram?. Heart Rhythm, 2021, 18, 79-87.	0.3	26
232	Caring for the pregnant woman with an inherited arrhythmia syndrome. Heart Rhythm, 2020, 17, 341-348.	0.3	25
233	A Complex Double Deletion in LMNA Underlies Progressive Cardiac Conduction Disease, Atrial Arrhythmias, and Sudden Death. Circulation: Cardiovascular Genetics, 2011, 4, 280-287.	5.1	24
234	TGFÎ²â€inducible early geneâ€1 (TIEG1) mutations in hypertrophic cardiomyopathy. Journal of Cellular Biochemistry, 2012, 113, 1896-1903.	1.2	24

#	Article	IF	Citations
235	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia, 2022, 38, 491-553.	0.5	24
236	Cardiac involvement in Dutch patients with sarcoglycanopathy: A crossâ€sectional cohort and followâ€up study. Muscle and Nerve, 2014, 50, 909-913.	1.0	23
237	Common and rare susceptibility genetic variants predisposing to Brugada syndrome in Thailand. Heart Rhythm, 2020, 17, 2145-2153.	0.3	23
238	Investigation on Sudden Unexpected Death in the Young (SUDY) in Europe: results of the European Heart Rhythm Association Survey. Europace, 2022, 24, 331-339.	0.7	23
239	Preferences of cardiologists and clinical geneticists for the future organization of genetic care in hypertrophic cardiomyopathy: a survey. Clinical Genetics, 2005, 68, 360-368.	1.0	22
240	Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm, 2011, 8, 1546-1552.	0.3	22
241	Variants in the SCN5A Promoter Associated With Various Arrhythmia Phenotypes. Journal of the American Heart Association, 2016, 5, .	1.6	22
242	Left Ventricular Isovolumetric Relaxation Time Is Prolonged in Fetal Long-QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005797.	2.1	22
243	Improving long QT syndrome diagnosis by a polynomial-based T-wave morphology characterization. Heart Rhythm, 2020, 17, 752-758.	0.3	22
244	50 Years of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) â€“ Time to Explore the Dark Side of the Moon. Heart Lung and Circulation, 2020, 29, 520-528.	0.2	22
245	Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. Heart Rhythm, 2020, 17, 1480-1486.	0.3	22
246	Asymmetry of parental origin in long QT syndrome: preferential maternal transmission of KCNQ1 variants linked to channel dysfunction. European Journal of Human Genetics, 2016, 24, 1160-1166.	1.4	21
247	SCN5A mutation type and topology are associated with the risk of ventricular arrhythmia by sodium channel blockers. International Journal of Cardiology, 2018, 266, 128-132.	0.8	21
248	Healthâ€related quality of life impact of a transcatheter pacing system. Journal of Cardiovascular Electrophysiology, 2018, 29, 1697-1704.	0.8	20
249	Incidence and predictors of implantable cardioverter-defibrillator therapy and its complications in idiopathic ventricular fibrillation patients. Europace, 2019, 21, 1519-1526.	0.7	20
250	The development and validation of an easy to use automatic QT-interval algorithm. PLoS ONE, 2017, 12, e0184352.	1.1	20
251	Stop-codon and C-terminal nonsense mutations are associated with a lower risk of cardiac events in patients with long QT syndrome type 1. Heart Rhythm, 2016, 13, 122-131.	0.3	19
252	Support vector machine-based assessment of the T-wave morphology improves long QT syndrome diagnosis. Europace, 2018, 20, iii113-iii119.	0.7	19

#	Article	IF	Citations
253	Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. Europace, 2021, 23, 887-897.	0.7	19
254	Human RyR2 (Ryanodine Receptor 2) Loss-of-Function Mutations. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010013.	2.1	18
255	The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Arrhythmia and Electrophysiology Review, 2016, 5, 45.	1.3	17
256	A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy. European Heart Journal, 2018, 39, 2898-2907.	1.0	17
257	Comparison of complications and shocks in paediatric and young transvenous and subcutaneous implantable cardioverter-defibrillator patients. Netherlands Heart Journal, 2018, 26, 612-619.	0.3	17
258	Heritability in genetic heart disease: the role of genetic background. Open Heart, 2019, 6, e000929.	0.9	17
259	Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia. JACC: Clinical Electrophysiology, 2019, 5, 387-394.	1.3	17
260	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Journal of Arrhythmia, 2021, 37, 481-534.	0.5	17
261	Life-threatening arrhythmias with autosomal recessive TECRL variants. Europace, 2021, 23, 781-788.	0.7	17
262	Mechanism of the effects of sodium channel blockade on the arrhythmogenic substrate of Brugada syndrome. Heart Rhythm, 2022, 19, 407-416.	0.3	17
263	KVLQT1, the rhythm of imprinting. Nature Genetics, 1997, 15, 113-115.	9.4	16
264	Substitution of a conserved alanine in the domain IIIS4â€“S5 linker of the cardiac sodium channel causes long QT syndrome. Cardiovascular Research, 2005, 67, 459-466.	1.8	16
265	Laminopathy presenting as familial atrial fibrillation. International Journal of Cardiology, 2010, 145, 394-396.	0.8	16
266	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 29-47.	0.5	16
267	Device orientation of a leadless pacemaker and subcutaneous implantable cardioverter-defibrillator in canine and human subjects and the effect on intrabody communication. Europace, 2018, 20, 1866-1871.	0.7	16
268	Spontaneous electrocardiographic fluctuations in Brugada syndrome: does it matter?. European Heart Journal, 2006, 27, 2493-2494.	1.0	15
269	Congenital Long QT Syndrome: An Update and Present Perspective in Saudi Arabia. Frontiers in Pediatrics, 2013, 1, 39.	0.9	15
270	Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 87-91.	1.4	15

#	Article	IF	Citations
271	Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). Journal of Cardiovascular Electrophysiology, 2018, 29, 1004-1009.	0.8	15
272	The brisk-standing-test for long QT syndrome in prepubertal school children: defining normal. Europace, 2018, 20, f108-f112.	0.7	15
273	Type 8 long QT syndrome: pathogenic variants in CACNA1C-encoded Cav1.2 cluster in STAC protein binding site. Europace, 2019, 21, 1725-1732.	0.7	15
274	Structurally Abnormal Myocardium Underlies Ventricular Fibrillation Storms in a Patient Diagnosed With the EarlyÂRepolarization Pattern. JACC: Clinical Electrophysiology, 2020, 6, 1395-1404.	1.3	15
275	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Heart Rhythm, 2020, 17, e269-e316.	0.3	15
276	Long-term performance of a novel communicating antitachycardia pacingâ€“enabled leadless pacemakerÂand subcutaneous implantable cardioverter-defibrillator system: A comprehensive preclinical study. Heart Rhythm, 2022, , .	0.3	15
277	Channelopathies in Children and Adults. PACE - Pacing and Clinical Electrophysiology, 2008, 31, S41-5.	0.5	14
278	Andersen-Tawil syndrome, scarier for the doctor than for the patient? Who, when, and how to treat. Europace, 2013, 15, 1690-1692.	0.7	14
279	Epicardial Substrate Ablation in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1306-1308.	2.1	14
280	Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview. Expert Opinion on Pharmacotherapy, 2008, 9, 537-549.	0.9	13
281	Minimal defibrillation thresholds and the correlation with implant position in subcutaneous implantableâ€defibrillator patients. Journal of Cardiovascular Electrophysiology, 2019, 30, 2441-2447.	0.8	13
282	In Children and Adolescents From Brugada Syndromeâ€“Families, Only SCN5A Mutation Carriers Develop a Type-1 ECG Pattern Induced By Fever. Circulation, 2020, 142, 89-91.	1.6	13
283	Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2021, 18, 1825-1832.	0.3	13
284	Maturation of hiPSC-derived cardiomyocytes promotes adult alternative splicing of SCN5A and reveals changes in sodium current associated with cardiac arrhythmia. Cardiovascular Research, 2023, 119, 167-182.	1.8	13
285	A deep learning approach identifies new ECG features in congenital long QT syndrome. BMC Medicine, 2022, 20, 162.	2.3	13
286	Ion Channels, the QT Interval, and Arrhythmias. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2048-2051.	0.5	12
287	Is There a Role for Implantable Cardioverter Defibrillators in Long QT Syndrome?. Journal of Cardiovascular Electrophysiology, 2002, 13, S110.	0.8	12
288	Diagnostic Performance of Various QTc Interval Formulas in a Large Family with Long QT Syndrome Type 3: Bazett's Formula Not So Bad After Allâ€ƒâ€¦. Annals of Noninvasive Electrocardiology, 2003, 8, 269-274.	0.5	12

#	Article	IF	Citations
289	I _{Ks} in Heart and Hearing, the Ear Can Do with Less than the Heart. Circulation: Cardiovascular Genetics, 2013, 6, 141-143.	5.1	12
290	Outpatient treatment with the wearable cardioverter defibrillator: clinical experience in two Dutch centres. Netherlands Heart Journal, 2017, 25, 312-317.	0.3	12
291	Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of aÂprospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator. Netherlands Heart Journal, 2017, 25, 574-580.	0.3	12
292	A phenotype-enhanced variant classification framework to decrease the burden of missense variants of uncertain significance in type 1 long QT syndrome. Heart Rhythm, 2022, 19, 435-442.	0.3	12
293	Inherited Arrhythmia Syndromes. Circulation Journal, 2007, 71, A12-A19.	0.7	11
294	Glibenclamide inhibition of ATP-sensitive K+ channels and ischemia-induced K+ accumulation in the mammalian heart. Pflugers Archiv European Journal of Physiology, 1989, 414, S176-S176.	1.3	10
295	Quality of Life in Young Adult Patients with a Cardiogenetic Condition Receiving an ICD for Primary Prevention of Sudden Cardiac Death. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 870-877.	0.5	10
296	Effect of Ascertainment Bias on Estimates of Patient Mortality in Inherited Cardiac Diseases. Circulation Genomic and Precision Medicine, 2018, 11, e001797.	1.6	10
297	Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST). Netherlands Heart Journal, 2022, 30, 84-95.	0.3	10
298	Prevalence of Short-Coupled Ventricular Fibrillation in a Large Cohort of Dutch Patients With Idiopathic Ventricular Fibrillation. Circulation, 2022, 145, 1437-1439.	1.6	10
299	Proarrhythmia Related to Sodium Channel Blockade: Mechanisms, Monitoring, Prevention and Management. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 136-141.	0.9	9
300	Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. Europace, 2022, 24, 296-305.	0.7	9
301	Letter Regarding Article by McNair et al, â€œSCN5A Mutation Associated With Dilated Cardiomyopathy, Conduction Disorder, and Arrhythmiaâ€. Circulation, 2005, 112, e9; author reply e9-10.	1.6	8
302	Inherited arrhythmia syndromes leading to sudden cardiac death in the young: A global update and an Indian perspective. Indian Heart Journal, 2014, 66, S49-S57.	0.2	8
303	Therapeutic approaches for Long QT syndrome type 3: an update. Europace, 2018, 20, 222-224.	0.7	8
304	A highly specific biomarker for Brugada syndrome. Also too good to be true?. European Heart Journal, 2020, 41, 2891-2893.	1.0	8
305	Dutch Outcome in Implantable CardioverterâEDefibrillator Therapy: Implantable CardioverterâEDefibrillatorâ€“Related Complications in a Contemporary Primary Prevention Cohort. Journal of the American Heart Association, 2021, 10, e018063.	1.6	8
306	Sex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms. Heart Rhythm, 2022, 19, 427-434.	0.3	8

#	Article	IF	Citations
307	Primary prevention with ICDs, are we on the right track?. Netherlands Heart Journal, 2009, 17, 92-94.	0.3	7
308	De novo mutation in the <scp>KCNQ1</scp> gene causal to Jervell and Langeâ€Nielsen syndrome. Clinical Genetics, 2014, 86, 492-495.	1.0	7
309	Next-generation sequencing using microfluidic PCR enrichment for molecular autopsy. BMC Cardiovascular Disorders, 2019, 19, 174.	0.7	7
310	BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variantsâ€"design and status. Netherlands Heart Journal, 2021, 29, 318-329.	0.3	7
311	Importance of Dedicated Units for the Management of Patients With Inherited Arrhythmia Syndromes. Circulation Genomic and Precision Medicine, 2021, 14, e003313.	1.6	7
312	Relation Between Basic and Clinical Electrophysiologic Characteristics in Brugada Syndrome: Facts or Fiction?. Journal of Cardiovascular Electrophysiology, 2003, 14, 412-414.	0.8	6
313	Sodium Channelopathies: Do We Really Understand What's Going On?. Journal of Cardiovascular Electrophysiology, 2011, 22, 590-593.	0.8	6
314	Channelopathies - Emerging Trends in The Management of Inherited Arrhythmias. Indian Pacing and Electrophysiology Journal, 2015, 15, 43-54.	0.3	6
315	Athletes with channelopathy may be eligible to play. Netherlands Heart Journal, 2018, 26, 146-153.	0.3	6
316	Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2022, 19, 1659-1665.	0.3	6
317	ClinicalÂparameters to optimize patient selection for subcutaneous and transvenous implantable defibrillator therapy. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 990-995.	0.5	5
318	Response by Wilde and Gollob to Letter Regarding Article, â€œReappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndromeâ€• Circulation, 2019, 139, 1760-1761.	1.6	5
319	SCN5A variants in Brugada syndrome: True, true false, or false true. Journal of Cardiovascular Electrophysiology, 2019, 30, 128-131.	0.8	5
320	Cardiogenetics, 25Âyears aÂgrowing subspecialism. Netherlands Heart Journal, 2020, 28, 39-43.	0.3	5
321	Management of Congenital Long-QT Syndrome: Commentary From the Experts. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009726.	2.1	5
322	Left Axis Deviation in Brugada Syndrome: Vectorcardiographic Evaluation during Ajmaline Provocation Testing Reveals Additional Depolarization Abnormalities. International Journal of Molecular Sciences, 2021, 22, 484.	1.8	5
323	Vasovagal syncope or ventricular fibrillation. Your diagnosis better be accurate. Clinical Autonomic Research, 2007, 17, 203-205.	1.4	4
324	Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide. Netherlands Heart Journal, 2015, 23, 182-189.	0.3	4

#	Article	IF	Citations
325	Catheter ablation in highly symptomatic Brugada patients: a Dutch case series. Clinical Research in Cardiology, 2020, 109, 560-569.	1.5	4
326	Value of Serial Heart Rate Variability Measurement for Prediction of Appropriate ICD Discharge in Patients with Heart Failure. Journal of Cardiovascular Electrophysiology, 2014, 25, 60-65.	0.8	3
327	Genotypeâ€“phenotype analysis of Jervell and Langeâ€Nielsen syndrome in six families from Saudi Arabia. Clinical Genetics, 2015, 87, 74-79.	1.0	3
328	A Potential Diagnostic Approach for Foetal Long-QT Syndrome, Developed and Validated in Children. Pediatric Cardiology, 2018, 39, 1413-1422.	0.6	3
329	The Î²-angle can help guide clinical decisions in the diagnostic work-up of patients suspected of Brugada syndrome: a validation study of the Î²-angle in determining the outcome of a sodium channel provocation test. Europace, 2021, 23, 2020-2028.	0.7	3
330	The Netherlands Sports Cardiology Map: aÂstep towards sports cardiology network medicine for patient and athlete care. Netherlands Heart Journal, 2021, 29, 129-134.	0.3	3
331	A new, sympathetic look at KATP channels in the heart. Cardiovascular Research, 1999, 43, 17-19.	1.8	2
332	ECG Quantification of Myocardial Scar Does Not Differ between Primary and Secondary Prevention ICD Recipients with Ischemic Heart Disease. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 192-197.	0.5	2
333	Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports. Europace, 2011, 13, 11-13.	0.7	2
334	Letter by Amin et al Regarding Article, â€œGenetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3â€² Untranslated Region of KCNQ1?â€• Circulation: Cardiovascular Genetics, 2016, 9, 580-580.	5.1	2
335	Role of Genetic Testing in Patients with Ventricular Arrhythmias in Apparently Normal Hearts. Cardiac Electrophysiology Clinics, 2016, 8, 515-523.	0.7	2
336	Genetic Causes in Cardiac Arrest Survivors. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	2
337	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. PLoS ONE, 2018, 13, e0203078.	1.1	2
338	Using registries to predict outcome: the implantable cardioverter-defibrillator in long QT syndrome. Europace, 2019, 21, 188-189.	0.7	2
339	Creating certainty out of uncertainty. European Heart Journal, 2019, 40, 839-841.	1.0	2
340	Pregnancy in women with Brugada syndrome: Is there an increased arrhythmia risk? A caseâ€series report. Journal of Cardiovascular Electrophysiology, 2021, , .	0.8	2
341	First Steps of Population Genomic Medicine in the Arrhythmia World: Pros and Cons. Circulation, 2022, 145, 892-895.	1.6	2
342	Subpopulations of Cardiomyocytes in the Embryonic Chicken Heart. Annals of the New York Academy of Sciences, 1990, 588, 354-356.	1.8	1

#	Article	IF	Citations
343	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 217-221.	0.9	1
344	Clinical Assessment of the Pathogenicity of Unknown Variants in Longâ€QT Syndrome: Does the Pendulum Swing Back?. Journal of Cardiovascular Electrophysiology, 2012, 23, 643-644.	0.8	1
345	Palpitations in a 19-year-old man, take a second look. Netherlands Heart Journal, 2013, 21, 205-205.	0.3	1
346	Palpitations in a 19-year-old man, take a second look. Netherlands Heart Journal, 2013, 21, 208-209.	0.3	1
347	Characterisation of familial idiopathic ventricular fibrillation linked to DPP6. European Heart Journal, 2013, 34, 4559-4559.	1.0	1
348	In memory of Hein Wellens: unique scientist, teacher, doctor and friend. Netherlands Heart Journal, 2020, 28, 439-440.	0.3	1
349	The â€˜presidentâ€™s drugâ€™. Netherlands Heart Journal, 2020, 28, 363-365.	0.3	1
350	Does function trump bioinformatics in Brugada syndrome-associated SCN5A mutation calling? Patients, computers, and patches. European Heart Journal, 2021, 42, 2864-2865.	1.0	1
351	From a Polish 3-Year-Old Boy Who Visited Maastricht to Automatic Detection Using Deep Learning: Brugada Syndrome Is Being Revolutionised. Canadian Journal of Cardiology, 2022, 38, 149-151.	0.8	1
352	Two siblings with early repolarization syndrome: clinical and genetic characterization by whole-exome sequencing. Europace, 2021, 23, 775-780.	0.7	1
353	Avoiding fatal implantable cardioverter-defibrillator complications in patients with catecholaminergic polymorphic ventricular tachycardia by not implanting them. Journal of Electrocardiology, 2022, 70, 2-3.	0.4	1
354	European Reference Network for rare, low prevalence, or complex diseases of the heart (ERN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302	1.0	1
355	Ventricular Arrhythmias and Sudden Death. , 0, , 80-95.		0
356	Bradycardia in LQT3 patients: insights from 0D models. , 0, , .		0
357	Exercise related syncope: when it?s not the heart. Clinical Autonomic Research, 2005, 15, 64-64.	1.4	0
358	Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Netherlands Heart Journal, 0, , 1.	0.3	0
359	Narrow QRS complexes intervening wide QRS complexes. Netherlands Heart Journal, 2012, 20, 518-518.	0.3	0
360	Narrow QRS complexes intervening wide QRS complexes. Netherlands Heart Journal, 2012, 20, 520-520.	0.3	0

#	Article	IF	Citations
361	Palpitations in a 19-year old man and a slow heart rate at rest. Netherlands Heart Journal, 2013, 21, 310-310.	0.3	0
362	Palpitations in a 19-year old man and a slow heart rate at rest. Netherlands Heart Journal, 2013, 21, 313-313.	0.3	0
363	An atypical arrhythmia. Netherlands Heart Journal, 2013, 21, 255-255.	0.3	0
364	An atypical arrhythmia. Netherlands Heart Journal, 2013, 21, 262-262.	0.3	0
365	Palpitations, should one worry?. Netherlands Heart Journal, 2013, 21, 159-160.	0.3	0
366	Palpitations, should one worry?. Netherlands Heart Journal, 2013, 21, 155-156.	0.3	0
367	Palpitations, once again. Netherlands Heart Journal, 2013, 21, 47-47.	0.3	0
368	Palpitations, once again. Netherlands Heart Journal, 2013, 21, 50-50.	0.3	0
369	Myocardial energetic impairment differs in pre-hypertrophic carriers with mutations in MYH7 and MYBPC3 - a PET and MRI study. European Heart Journal, 2013, 34, P3885-P3885.	1.0	0
370	Exome sequencing of multiple affected individuals from an Irish family with Brugada Syndrome uncovers a novel locus for the disorder. European Heart Journal, 2013, 34, P2289-P2289.	1.0	0
371	A common arrhythmia, not so common at an old age. Netherlands Heart Journal, 2014, 22, 88-88.	0.3	0
372	An unexpected ECG finding. Netherlands Heart Journal, 2015, 23, 613-616.	0.3	0
373	An unexpected ECG finding. Netherlands Heart Journal, 2015, 23, 608-608.	0.3	0
374	From Whole Exome Sequencing to Patientâ€Specific Therapy: Another Example of How Basic Research Pays Off in Patient Care. Journal of the American Heart Association, 2015, 4, .	1.6	0
375	Familial Disease Is Not Always Genetic: A Family With Atrioventricular Block and Mitral Regurgitation. Canadian Journal of Cardiology, 2017, 33, 554.e9-554.e11.	0.8	0
376	Response by Veerman et al to Letter Regarding Article, â€œThe Brugada Syndrome Susceptibility Gene HEY2 Modulates Cardiac Transmural Ion Channel Patterning and Electrical Heterogeneityâ€• Circulation Research, 2017, 121, e21.	2.0	0
377	P4373Post systolic shortening in the apex of the left ventricular is a typical finding in patients with PLN mutation. European Heart Journal, 2019, 40, .	1.0	0
378	COVID-19 does not only disturb our social rhythm. Heart Rhythm, 2021, 18, 510-511.	0.3	0

#	Article	IF	Citations
379	Oral contraceptives and their effect on arrhythmogenesis in long QT syndrome: Does it matter?. Heart Rhythm, 2021, , .	0.3	0
380	Patients with a DPP6 risk- haplotype for familial idiopathic ventricular fibrillation have normal left systolic function but abnormal deformation. European Heart Journal Cardiovascular Imaging, 2021, 22, .	0.5	0
381	Normalization of global longitudinal strain after a 30-seconds exercise bout in elite athletes. European Heart Journal, 2021, 42, .	1.0	0
382	ç¬¬20å›žæ—¥æœ¬å¿ƒé›»å¦ä¼šå¦ è¡“é›†ä¼š å±±ç”°å'Œç”Ÿæ‹›è•è¬›æ¼”æŠ„éŒ². Japanese Journal of Electrocardiology, 2003, 23, 41.	0.0	0
383	Andersen-Tawil syndrome: Overlapping clinical features with Noonan syndrome?. European Journal of Medical Genetics, 2021, 65, 104382.	0.7	0
384	Importance of Validating Guideline Recommendations. Circulation Journal, 2020, 84, 2136-2137.	0.7	0
385	Biomarkers in inherited arrhythmias: necessity for validation and collaboration. European Heart Journal, 2020, 41, 4523-4524.	1.0	0
386	Hinge point fibrosis is highly prevalent in male elite water polo players. European Heart Journal, 2020, 41, .	1.0	0
387	Normalization of global longitudinal strain after 20 squats in elite athletes. European Heart Journal Cardiovascular Imaging, 2022, 23, .	0.5	0
388	Aortic dilatation using cardiac magnetic resonance in asymptomatic ELITE athletes. European Journal of Preventive Cardiology, 2022, 29, .	0.8	0
389	Late gadolinium enhancement of the hinge point is a common finding in asymptomatic ELITE athletes. European Journal of Preventive Cardiology, 2022, 29, .	0.8	0
390	Clinical risk factors associated with ventricular fibrillation during first ST-elevation myocardial infarction. Europace, 2022, 24, .	0.7	0